Chicago Partners Investment Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.6M Sell
18,216
-3,758
-17% -$3.84M 0.43% 50
2026
Q1
$20.2M Buy
21,974
+570
+3% +$578K 0.45% 50
2025
Q4
$22.8M Buy
21,404
+162
+0.8% +$155K 0.56% 40
2025
Q3
$17.4M Sell
21,242
-80
-0.4% -$59.5K 0.46% 51
2025
Q2
$17M Buy
21,322
+111
+0.5% +$86.3K 0.49% 45
2025
Q1
$16.5M Buy
21,211
+2,314
+12% +$1.93M 0.55% 42
2024
Q4
$14.9M Buy
18,897
+369
+2% +$306K 0.49% 46
2024
Q3
$16.7M Sell
18,528
-216
-1% -$194K 0.6% 39
2024
Q2
$14.8M Sell
18,744
-160
-0.8% -$128K 0.57% 40
2024
Q1
$14.1M Sell
18,904
-527
-3% -$375K 0.6% 37
2023
Q4
$12.3M Sell
19,431
-1,502
-7% -$877K 0.57% 40
2023
Q3
$12.1M Sell
20,933
-491
-2% -$253K 0.65% 32
2023
Q2
$9.74M Buy
21,424
+1,867
+10% +$783K 0.51% 43
2023
Q1
$7.5M Buy
19,557
+11,091
+131% +$3.74M 0.44% 53
2022
Q4
$2.88M Buy
8,466
+931
+12% +$330K 0.18% 122
2022
Q3
$2.75M Buy
7,535
+71
+1% +$22.5K 0.2% 114
2022
Q2
$2.46M Sell
7,464
-2,388
-24% -$717K 0.18% 112
2022
Q1
$2.91M Buy
9,852
+5,043
+105% +$1.3M 0.22% 95
2021
Q4
$1.13M Buy
4,809
+57
+1% +$14.4K 0.08% 202
2021
Q3
$1.25M Buy
4,752
+83
+2% +$20.5K 0.09% 194
2021
Q2
$1.14M Sell
4,669
-1,057
-18% -$212K 0.08% 192
2021
Q1
$1.07M Buy
5,726
+1,627
+40% +$318K 0.09% 192
2020
Q4
$845K Buy
4,099
+168
+4% +$25.1K 0.08% 197
2020
Q3
$515K Sell
3,931
-196
-5% -$30.3K 0.06% 230
2020
Q2
$662K Sell
4,127
-33
-0.8% -$5.07K 0.08% 182
2020
Q1
$654K Buy
4,160
+833
+25% +$114K 0.1% 157
2019
Q4
$471K Buy
3,327
+287
+9% +$33.3K 0.06% 223
2019
Q3
$328K Sell
3,040
-5
-0.2% -$557 0.05% 248
2019
Q2
$327K Buy
3,045
+66
+2% +$7.77K 0.05% 243
2019
Q1
$343K Sell
2,979
-1,334
-31% -$162K 0.05% 224
2018
Q4
$500K Sell
4,313
-589
-12% -$65.8K 0.07% 184
2018
Q3
$527K Buy
4,902
+591
+14% +$59.1K 0.08% 179
2018
Q2
$368K Buy
4,311
+2
+0% +$164 0.06% 211
2018
Q1
$333K Buy
4,309
+1
+0% +$81 0.06% 202
2017
Q4
$364K Sell
4,308
-68
-2% -$5.79K 0.06% 197
2017
Q3
$374K Buy
4,376
+551
+14% +$45.2K 0.06% 190
2017
Q2
$299K Buy
3,825
+1,525
+66% +$124K 0.08% 148
2017
Q1
$193K Sell
2,300
-44
-2% -$3.52K 0.05% 192
2016
Q4
$172K Buy
2,344
+44
+2% +$3.28K 0.06% 185
2016
Q3
$185K Hold
2,300
0.07% 178
2016
Q2
$181K Hold
2,300
0.09% 141
2016
Q1
$166K Hold
2,300
0.09% 145
2015
Q4
$194K Hold
2,300
0.09% 156
2015
Q3
$192K Hold
2,300
0.11% 133
2015
Q2
$192K Sell
2,300
-122
-5% -$9.3K 0.09% 138
2015
Q1
$167K Buy
2,422
+122
+5% +$8.69K 0.07% 142
2014
Q4
$159K Buy
+2,300
New +$155K 0.07% 138

Other funds holding LLY

Chicago Partners Investment Group's LLY Position: Q2 2026 in Review

Chicago Partners Investment Group reduced its Eli Lilly (LLY) stake by 17% in Q2 2026, selling an estimated $3.84M and leaving 18,216 shares worth $21.6M. The position accounts for 0.43% of the portfolio, ranked #50.

Chicago Partners Investment Group first reported a position in LLY in Q4 2014 and has held it in 47 quarters since. The position peaked at $22.8M in Q4 2025. 4,600 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Chicago Partners Investment Group held 18,216 shares of Eli Lilly worth $21.6M as of Q2 2026.
  • Chicago Partners Investment Group sold 3,758 Eli Lilly shares in Q2 2026, an estimated $3.84M.
  • Eli Lilly made up 0.43% of Chicago Partners Investment Group's portfolio in Q2 2026, its #50 holding.
  • Chicago Partners Investment Group first reported a position in Eli Lilly in Q4 2014 and has held it in 47 quarters since.
  • Chicago Partners Investment Group's Eli Lilly position peaked at $22.8M in Q4 2025.
  • 4,600 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.